Complications and side effects · people with CLI who were not suitable for revascularisation and showed no improvement in response to the best standard therapy
It is very uncertain whether intramuscular injection of bone marrow mononuclear cells (BMMNC) changes side effects and complications ( compared with control (very low certainty).
1 finding from 1 review
Intervention not reported
Complete clot lysis (intermediate, 6 months to under 5 years after treatment) · patients diagnosed with acute DVT
The intervention probably leads to higher complete clot lysis (intermediate, 6 months to under 5 years after… (moderate certainty).
1 finding from 1 review
Intervention not reported
Bleeding (early, up to 1 month after treatment) · patients diagnosed with acute DVT
The intervention probably leads to higher bleeding (early, up to 1 month after treatment) (moderate certainty).
1 finding from 1 review
Intervention not reported
Post‐thrombotic syndrome (intermediate, 6 months to under 5 years after treatment) · patients diagnosed with acute DVT
The intervention probably leads to lower post‐thrombotic syndrome (intermediate, 6 months to under 5 years… (moderate certainty).
1 finding from 1 review
Intervention not reported
Post‐thrombotic syndrome (late, 5 years · patients diagnosed with acute DVT
The intervention probably leads to lower post‐thrombotic syndrome (late, 5 years (moderate certainty).
1 finding from 1 review
Intervention not reported
Success of prosthetic rehabilitation (preference) (1 day) · adults over the age of 50 with a unilateral transfemoral amputation
1 finding from 1 review
Intervention not reported
Adverse effects (1 day) · adults over the age of 50 with a unilateral transfemoral amputation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Incidence of recurrent VTE1 after initial treatment (up to 15 days) · patients with venous thromboembolism.
LMWH probably leads to lower incidence of recurrent VTE1 after initial treatment (up to 15 days) compared with UFH (moderate certainty).
1 finding from 1 review
Recurrent VTE · patients with venous thromboembolism.
LMWH probably leads to lower incidence of recurrent VTE1 (3 months compared with UFH (moderate certainty).
2 findings from 1 review
Reduction in thrombus size (pre‐ and post‐treatment venograms) · patients with venous thromboembolism.
LMWH may leads to lower reduction in thrombus size (pre‐ and post‐treatment venograms) compared with UFH (low certainty).
1 finding from 1 review
Major bleeding · patients with venous thromboembolism.
LMWH probably leads to lower incidence of major haemorrhagic episodes (during initial treatment ‐… compared with UFH (moderate certainty).
1 finding from 1 review
Overall mortality (end of · patients with venous thromboembolism.
LMWH showed no clear difference in overall mortality (end of compared with UFH (moderate certainty).
1 finding from 1 review
Intervention not reported
Early postoperative non‐thrombotic complications · Individuals with peripheral arterial disease
The intervention showed no clear difference in early postoperative non‐thrombotic complications (high certainty).
1 finding from 1 review
Intervention not reported
Procedural mortality · Individuals with peripheral arterial disease
The intervention showed no clear difference in procedural mortality (high certainty).
1 finding from 1 review
Intervention not reported
Clinical improvement · Individuals with peripheral arterial disease
The intervention showed no clear difference in clinical improvement (low certainty).
1 finding from 1 review
Intervention not reported
Amputation · Individuals with peripheral arterial disease
The intervention showed no clear difference in amputation (high certainty).
1 finding from 1 review
Intervention not reported
Primary patency · Individuals with peripheral arterial disease
The intervention probably leads to higher primary patency (moderate certainty).
1 finding from 1 review
Intervention not reported
Primary patency · Individuals with peripheral arterial disease
The intervention showed no clear difference in primary patency (high certainty).
1 finding from 1 review
Intervention not reported
Mortality within · Individuals with peripheral arterial disease
The intervention showed no clear difference in mortality within (high certainty).
1 finding from 1 review
Recurrent VTE · patients with symptomatic VTE requiring long term treatment (3 months) for symptomatic VTE
LMWH showed no clear difference in incidence of recurrent VTE (treatment duration 3 months) compared with VKA (moderate certainty).
1 finding from 1 review